EP1862852A1 - Developer concentrate - Google Patents

Developer concentrate Download PDF

Info

Publication number
EP1862852A1
EP1862852A1 EP07010793A EP07010793A EP1862852A1 EP 1862852 A1 EP1862852 A1 EP 1862852A1 EP 07010793 A EP07010793 A EP 07010793A EP 07010793 A EP07010793 A EP 07010793A EP 1862852 A1 EP1862852 A1 EP 1862852A1
Authority
EP
European Patent Office
Prior art keywords
concentrate according
developer concentrate
amount
per liter
working solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07010793A
Other languages
German (de)
French (fr)
Other versions
EP1862852B1 (en
Inventor
Wolfgang Zehner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orochemie GmbH and Co KG
Original Assignee
Orochemie Duerr and Pflug & Co KG GmbH
Orochemie Duerr and Pflug GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orochemie Duerr and Pflug & Co KG GmbH, Orochemie Duerr and Pflug GmbH and Co KG filed Critical Orochemie Duerr and Pflug & Co KG GmbH
Publication of EP1862852A1 publication Critical patent/EP1862852A1/en
Application granted granted Critical
Publication of EP1862852B1 publication Critical patent/EP1862852B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C5/00—Photographic processes or agents therefor; Regeneration of such processing agents
    • G03C5/26—Processes using silver-salt-containing photosensitive materials or agents therefor
    • G03C5/264—Supplying of photographic processing chemicals; Preparation or packaging thereof
    • G03C5/266—Supplying of photographic processing chemicals; Preparation or packaging thereof of solutions or concentrates
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C5/00—Photographic processes or agents therefor; Regeneration of such processing agents
    • G03C5/26—Processes using silver-salt-containing photosensitive materials or agents therefor
    • G03C5/29—Development processes or agents therefor
    • G03C5/30—Developers
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C5/00—Photographic processes or agents therefor; Regeneration of such processing agents
    • G03C5/26—Processes using silver-salt-containing photosensitive materials or agents therefor
    • G03C5/29—Development processes or agents therefor
    • G03C5/30—Developers
    • G03C2005/3007—Ascorbic acid
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C2200/00—Details
    • G03C2200/44—Details pH value
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C5/00—Photographic processes or agents therefor; Regeneration of such processing agents
    • G03C5/26—Processes using silver-salt-containing photosensitive materials or agents therefor
    • G03C5/29—Development processes or agents therefor
    • G03C5/30—Developers
    • G03C5/3028—Heterocyclic compounds
    • G03C5/3035—Heterocyclic compounds containing a diazole ring

Definitions

  • the invention relates to a developer for photosensitive film material according to the preamble of claim 1.
  • Such developers are in a variety of forms on the market. They generally serve to convert, by a reducing agent (developing agent), silver ions or other suitable metal ions contained in the photosensitive layer and sensitized by exposure to light into metallic silver.
  • a reducing agent developer agent
  • silver ions or other suitable metal ions contained in the photosensitive layer and sensitized by exposure to light into metallic silver.
  • the present invention is intended to provide a developer concentrate for photosensitive film material, which is distinguished by particularly good long-term stability under use conditions.
  • the developer according to the invention has as further advantages that it is free of hydroquinone and of GDA (glutaraldehyde adduct). It is also characterized by a very high development activity. It also has excellent yield, especially in roll developing machines.
  • the most important component in terms of quantity is the solvent. This is generally chosen so that it is compatible with the film layer to be developed, so it wets and allows an exchange of solutes with the film layer.
  • a water-based solvent is suggested, which means that this solvent comprises predominantly or completely water.
  • adjuvants may be added to the water which promote wetting of the film layer, optionally swelling of the film layer and later drying of the film layer.
  • the developing agent serves to convert the metal ions of the photosensitive layer, insofar as they have been activated by light, into elemental metal.
  • known developing agents include hydroquinone and other substances that are undesirable for environmental or potential health reasons.
  • One class of reducing agent used in the developer of the present invention includes ascorbic acid and derivatives of ascorbic acid, especially salts thereof. These are particularly advantageous in terms of environmental protection.
  • Development enhancers used in the invention include pyrazolidinone derivatives containing two nitrogen atoms in a five-membered ring.
  • the five-membered ring may carry further aliphatic or aromatic groups.
  • Preferred examples of such pyrazolidinone derivative developing agents are 4-hydroxymethyl-4-methyl-1-phenyl-3-pyrazolidinone, 1-phenylpyrazolidin-3-one and 1-phenyl-4-methyl-3-pyrazolidinone. These substances are also known under the trade names Dimezone S, Phenidone A and Phenidone B.
  • a development inhibitor is added to the developer.
  • These are preferably alkali halides, in particular those with heavier anions, preferably potassium bromide or sodium bromide.
  • the pH of the use solution be maintained within a given window of from about 8.5 to about 12, preferably from about 9.7 to about 11.2.
  • alkalis preferably potassium hydroxide or sodium hydroxide.
  • the pH can also be stabilized by salts of a weak acid in the desired alkaline range, in particular salts of weak organic or inorganic acids, preferably potassium carbonate, sodium tetraborate, sodium metaborate. You can also use mixtures of alkalis and salts.
  • the development result is advantageously influenced if the developer is additionally added a complexing agent.
  • complexing agents are preferably organic acids with small chain length, which contain nitrogen groups, more preferably additionally short aliphatic groups.
  • Preferred complexing agents are diethyltriamine pentaethanoic acid (DTPA), ethylenediaminetetraethanoic acid (EDTA), hydroxyethylethylenediaminetriacetic acid (HEDTA) and nitrilotriethanoic acid (NTA) and salts of the aforementioned acids.
  • a ready-to-use developer solution is adversely affected by oxidation in its properties.
  • an antioxidant to the developer.
  • Suitable for this purpose are generally not completely oxidized acids and salts thereof, in particular sulfites such as potassium sulfite, potassium hydrogen sulfite, potassium metabisulfite and sodium bisulfite.
  • a solubilizer can be used.
  • These may be polyhydric alcohols, in particular diols or glycols. Diethylene glycol and triethylene glycol are preferably used here.
  • agents belonging to the group of azoles in particular of the benzotriazole, indazole, mercaptotetrazole and imidazole type), in particular 5-mercapto-1-phenyl-1,2,3,4-tetrazole (PMT ), 1-H-benzotriazole, 5-methylbenzotriazole, 6-nitrobenzimidazole, 5-nitroindazole.
  • compositions of embodiments give an overview of the concentration in which the various components in a Use solution in grams per liter of working solution may be present.
  • the concentrations are recommended, which are recommended if a considered component alone forms the corresponding agent. It is understood that it is also possible to use mixtures of substances that are equally suitable for the same component of the developer, in which case the amounts used are selected such that the corresponding overall effect is obtained. Thus, for example, according to the following table for the different complexing agents in each case the same amount used. In this case, one can then simply replace the omitted portion of a complexing agent with an appropriate amount of another complexing agent.
  • Example 1 Developer for X-ray film processor
  • concentration data in the above description and claims refer, as indicated, to one liter of working solution and not to the concentrate.
  • concentrations in the concentrate are greater according to the prescribed dilution ratio for the concentrate. This dilution ratio is about 1.5 to 5 for a practical developer for roll-fed development machines, and about 0.5 to 1 for roll-free processors (film is moved around the edges by the tanks).

Abstract

Developer concentrate (A), for photosensitive film material, comprises a solvent based on water, an adjusting agent, which adjusts the alkali pH-value of the solvent and a formulating agent such as ascorbic acid or its salt, where the pH of the obtained solution is diluted to 8.5-12.

Description

Die Erfindung betrifft einen Entwickler für lichtempfindliches Filmmaterial gemäß dem Oberbegriff des Anspruches 1.The invention relates to a developer for photosensitive film material according to the preamble of claim 1.

Derartige Entwickler sind in vielfältiger Form auf dem Markt. Sie dienen generell dazu, durch ein Reduktionsmittel (Entwicklungsmittel) Silberionen oder andere geeignete Metallionen, die in der lichtempfindlichen Schicht enthalten sind und durch Lichteinwirkung sensibilisiert sind, in metallisches Silber umwandelt.Such developers are in a variety of forms on the market. They generally serve to convert, by a reducing agent (developing agent), silver ions or other suitable metal ions contained in the photosensitive layer and sensitized by exposure to light into metallic silver.

Bei Entwicklern, die in Entwicklungsautomaten verwendet werden, die große Volumina an Entwicklern enthalten, stellt sich das Problem der Langzeitstabilität des gebrauchsfertigen Entwicklers ohne Regenerierung. Nach Standzeiten von einigen Tagen oder Wochen lässt die Entwicklungsqualität deutlich nach und der gesamte Entwickler muss durch neuen Entwickler ersetzt werden.For developers used in development machines that contain large volumes of developers, the problem of the long-term stability of the ready-to-use developer without regeneration arises. After a service life of a few days or weeks, the development quality decreases significantly and the entire developer must be replaced by new developers.

Durch die vorliegende Erfindung soll ein Entwicklerkonzentrat für lichtempfindliches Filmmaterial geschaffen werden, welches sich durch besonders gute Langzeitstabilität unter Einsatzbedingungen auszeichnet.The present invention is intended to provide a developer concentrate for photosensitive film material, which is distinguished by particularly good long-term stability under use conditions.

Diese Aufgabe ist erfindungsgemäß gelöst durch einen Entwickler mit den in Anspruch 1 angegebenen Merkmalen.This object is achieved by a developer having the features specified in claim 1.

Der erfindungemäße Entwickler hat als weitere Vorteile, dass er frei von Hydrochinon und von GDA (Glutardialdehydaddukt) ist. Er zeichnet sich auch durch eine sehr hohe Entwicklungsaktivität aus. Er hat auch eine ausgezeichnete Ergiebigkeit, insbesondere in Rollen-Entwicklungsmaschinen.The developer according to the invention has as further advantages that it is free of hydroquinone and of GDA (glutaraldehyde adduct). It is also characterized by a very high development activity. It also has excellent yield, especially in roll developing machines.

Vorteilhafte Weiterbildungen der Erfindung sind Gegenstand der Unteransprüche.Advantageous developments of the invention are the subject of the dependent claims.

Nachstehend werden zu einzelnen Komponenten eines erfindungsgemäßen Entwicklerkonzentrates, welche in diesem enthalten sein können, allgemeine Anmerkungen gegeben.Hereinbelow, general comments will be made on individual components of a developer concentrate of the invention which may be included therein.

Mengenmäßig die wichtigste Komponente ist das Lösungsmittel. Dieses ist generell so gewählt, dass es mit der zu entwickelnden Filmschicht kompatibel ist, also diese benetzt und einen Austausch gelöster Stoffe mit der Filmschicht ermöglicht. Es wird ein Lösungsmittel auf Wasserbasis vorgeschlagen, was bedeutet, dass dieses Lösungsmittel überwiegend oder ganz Wasser umfasst. Dem Wasser können jedoch Hilfsstoffe zugefügt sein, welche die Benetzung der Filmschicht, gegebenenfalls ein Quellen der Filmschicht und später ein Trocknen der Filmschicht begünstigen.The most important component in terms of quantity is the solvent. This is generally chosen so that it is compatible with the film layer to be developed, so it wets and allows an exchange of solutes with the film layer. A water-based solvent is suggested, which means that this solvent comprises predominantly or completely water. However, adjuvants may be added to the water which promote wetting of the film layer, optionally swelling of the film layer and later drying of the film layer.

Das Entwicklungsmittel dient, wie üblich, dazu, die Metallionen der lichtempfindlichen Schicht, soweit sie durch Licht aktiviert wurden, in elementares Metall umzuwandeln. Bekannte Entwicklungsmittel umfassen zum Beispiel Hydrochinon und andere Substanzen, die aus Gründen des Umweltschutzes oder potentieller gesundheitlicher Gefährdung nicht erwünscht sind.The developing agent, as usual, serves to convert the metal ions of the photosensitive layer, insofar as they have been activated by light, into elemental metal. For example, known developing agents include hydroquinone and other substances that are undesirable for environmental or potential health reasons.

Eine Klasse beim erfindungsgemäßen Entwickler verwendeter Reduktionsmittel umfasst Ascorbinsäure und Derivate der Ascorbinsäure, insbesondere Salze derselben. Diese sind im Hinblick auf den Umweltschutz besonders vorteilhaft.One class of reducing agent used in the developer of the present invention includes ascorbic acid and derivatives of ascorbic acid, especially salts thereof. These are particularly advantageous in terms of environmental protection.

Bei der Erfindung verwendete Entwicklungsverstärker umfassen Pyrazolidinon-Derivate, die in einem Fünfring zwei Stickstoffatome enthalten. Der Fünferring kann weitere aliphatische oder aromatische Gruppen tragen.Development enhancers used in the invention include pyrazolidinone derivatives containing two nitrogen atoms in a five-membered ring. The five-membered ring may carry further aliphatic or aromatic groups.

Bevorzugte Beispiele für derartige Pyrazolidinonderivat-Entwicklungsmittel sind 4-Hydroxymethyl-4-methyl-1-phenyl-3-pyrazolidinon, 1-Phenylpyrazolidin-3-on und 1-Phenyl-4-methyl-3-pyrazolidinon. Diese Substanzen sind auch unter den Handelsnamen Dimezone S, Phenidon A und Phenidon B bekannt.Preferred examples of such pyrazolidinone derivative developing agents are 4-hydroxymethyl-4-methyl-1-phenyl-3-pyrazolidinone, 1-phenylpyrazolidin-3-one and 1-phenyl-4-methyl-3-pyrazolidinone. These substances are also known under the trade names Dimezone S, Phenidone A and Phenidone B.

Die Vorteile dieser Substanzen liegen in einer intensiveren Schwärzung der belichteten Filmbereiche (Superadditivität).The advantages of these substances lie in a more intense blackening of the exposed film areas (superadditivity).

Legt man größeren Wert auf die Qualität und die Gleichförmigkeit des Entwicklungsergebnisses als auf die Kürze des Entwicklungsprozesses, so wird dem Entwickler ein Entwicklungsverzögerer zugesetzt. Es handelt sich hierbei bevorzugt um Alkalihalogenide, insbesondere solche mit schwereren Anionen, bevorzugt Kaliumbromid oder Natriumbromid.If more emphasis is placed on the quality and uniformity of the development result than on the brevity of the development process, a development inhibitor is added to the developer. These are preferably alkali halides, in particular those with heavier anions, preferably potassium bromide or sodium bromide.

Für die Langzeitstabilität des Entwicklers ist es von großer Bedeutung, dass der pH-Wert der Gebrauchslösung innerhalb eines vorgegebenen Fensters von etwa 8.5 bis etwa 12 gehalten wird, vorzugsweise von etwa 9,7 bis etwa 11,2.For the long-term stability of the developer, it is of great importance that the pH of the use solution be maintained within a given window of from about 8.5 to about 12, preferably from about 9.7 to about 11.2.

Man kann hierzu zum einen einfach Laugen verwenden, bevorzugt Kaliumhydroxid oder Natriumhydroxid. Man kann den pH-Wert aber auch durch Salze einer schwachen Säure im gewünschten alkalischen Bereich stabilisieren, insbesondere Salze von schwachen organischen oder anorganischen Säuren, bevorzugt Kaliumcarbonat, Natriumtetraborat, Natriummetaborat. Auch kann man Mischungen aus Laugen und Salzen verwenden.For this purpose, one can simply use alkalis, preferably potassium hydroxide or sodium hydroxide. However, the pH can also be stabilized by salts of a weak acid in the desired alkaline range, in particular salts of weak organic or inorganic acids, preferably potassium carbonate, sodium tetraborate, sodium metaborate. You can also use mixtures of alkalis and salts.

Das Entwicklungsergebnis wird vorteilhaft beeinflusst, wenn man dem Entwickler zusätzlich ein Komplexierungsmittel zugibt. Es handelt sich hierbei bevorzugt um organische Säuren mit kleiner Kettenlänge, welche Stickstoffgruppen enthalten, nochmals bevorzugt zusätzlich kurze aliphatische Gruppen. Bevorzugte Komplexierungsmittel sind Diethyltriaminpentaethansäure (DTPA), Ethylendiamintetraethansäure (EDTA), Hydroxyethylethylendiamintriessigsäure (HEDTA) und Nitrilotriethansäure (NTA) sowie Salze der vorgenannten Säuren.The development result is advantageously influenced if the developer is additionally added a complexing agent. These are preferably organic acids with small chain length, which contain nitrogen groups, more preferably additionally short aliphatic groups. Preferred complexing agents are diethyltriamine pentaethanoic acid (DTPA), ethylenediaminetetraethanoic acid (EDTA), hydroxyethylethylenediaminetriacetic acid (HEDTA) and nitrilotriethanoic acid (NTA) and salts of the aforementioned acids.

Eine gebrauchsfertige Entwicklerlösung wird durch Oxidation in ihren Eigenschaften negativ beeinflusst. Zur Verbesserung der Langzeitstabilität eines gebrauchsfertigen Entwicklers gegen Oxidation kann man daher dem Entwickler ein Oxidationsschutzmittel zusetzen. Hierfür sind generell geeignet die nicht voll aufoxidierten Säuren und Salze derselben, insbesondere Sulfite wie Kaliumsulfit, Kaliumhydrogensulfit, Kaliummetabisulfit und Natriumhydrogensulfit.A ready-to-use developer solution is adversely affected by oxidation in its properties. To improve the long-term stability of a ready-to-use developer against oxidation, it is therefore possible to add an antioxidant to the developer. Suitable for this purpose are generally not completely oxidized acids and salts thereof, in particular sulfites such as potassium sulfite, potassium hydrogen sulfite, potassium metabisulfite and sodium bisulfite.

Zur besseren und gleichmäßigen Lösung des Entwicklungsmittels in dem Lösungsmittel kann ein Lösungsvermittler verwendet werden. Hierbei kann es sich um mehrwertige Alkohole, insbesondere Diole bzw. Glycole, handeln. Bevorzugt werden hier Diethylenglycol und Triethylenglycol verwendet.For a better and uniform solution of the developing agent in the solvent, a solubilizer can be used. These may be polyhydric alcohols, in particular diols or glycols. Diethylene glycol and triethylene glycol are preferably used here.

Schließlich wird die Qualität des Entwicklungsergebnisses auch durch ein Antischleiermittel verbessert. Besonders eignen sich Mittel, die zur Gruppe der Azole (insbesondere vom Typ Benzotriazol, vom Typ Indazol, vom Typ Mercaptotetrazol und vom Typ Imidazol) gehören, insbesondere 5-Mercapto-1-phenyl-1,2,3,4-tetrazol (PMT), 1-H-Benzotriazol, 5-Methylbenzotriazol, 6-Nitrobenzimidazol, 5-Nitroindazol.Finally, the quality of the development result is also improved by an antifoggant. Particularly suitable are agents belonging to the group of azoles (in particular of the benzotriazole, indazole, mercaptotetrazole and imidazole type), in particular 5-mercapto-1-phenyl-1,2,3,4-tetrazole (PMT ), 1-H-benzotriazole, 5-methylbenzotriazole, 6-nitrobenzimidazole, 5-nitroindazole.

Die nachstehenden Tabellen der Zusammensetzungen von Ausführungsbeispielen geben einen Überblick über die Konzentration, in welcher die verschiedenen Komponenten in einer Gebrauchslösung in Gramm pro Liter Gebrauchslösung vorliegen können.The tables below of the compositions of embodiments give an overview of the concentration in which the various components in a Use solution in grams per liter of working solution may be present.

Dabei sind jeweils die Konzentrationen angegeben, die empfohlen werden, wenn eine betrachtete Komponente allein das entsprechende Mittel bildet. Es versteht sich, dass man von Substanzen, die gleichermaßen für die gleiche Komponente des Entwicklers in Frage kommen, auch Mischungen verwenden kann, wobei dann die Einsatzmengen so gewählt werden, dass die entsprechende Gesamtwirkung erhalten wird. So ist zum Beispiel gemäß der folgenden Tabelle für die verschiedenen Komplexierungsmittel jeweils die selbe Einsatzmenge angegeben. In diesem Falle kann man dann einfach den weggelassenen Anteil eines Komplexierungsmittels durch eine entsprechende Menge eines anderen Komplexierungsmittels ersetzen.In each case, the concentrations are recommended, which are recommended if a considered component alone forms the corresponding agent. It is understood that it is also possible to use mixtures of substances that are equally suitable for the same component of the developer, in which case the amounts used are selected such that the corresponding overall effect is obtained. Thus, for example, according to the following table for the different complexing agents in each case the same amount used. In this case, one can then simply replace the omitted portion of a complexing agent with an appropriate amount of another complexing agent.

Für das pH-Einstellmittel sind dagegen die Einsatzmengen für die verschiedenen genannten Substanzen sehr unterschiedlich. Man erkennt, dass man zum Ersetzen einer vorgegebenen Menge an Natriumtretraborat eine Menge an Kaliumcarbonat verwenden muss, die etwas das sieben- bis neunfache der zu ersetzenden Menge Natriumtretraborat beträgt.For the pH adjusting agent, however, the amounts used for the various substances mentioned are very different. It will be appreciated that to replace a given amount of sodium tetraborate, one must use an amount of potassium carbonate that is about seven to nine times the amount of sodium tetraborate to be replaced.

Nachstehend werden bevorzugte praktische Ausführungsbeispiele für erfindungsgemäße Entwickler beschrieben.Hereinafter, preferred practical embodiments for developers according to the present invention will be described.

Beispiel 1: Entwickler für Röntgenfilm-EntwicklungsaufautomatenExample 1: Developer for X-ray film processor

Bestandteilcomponent Mengeamount [g/Liter Gebrauchslösung][g / liter working solution] Wasserwater ad 1000 mlad 1000 ml Dissolvine D 88 Art.Nr. 848534 (*)Dissolvine D 88 Art.No. 848534 (*) 6,6606,660 Kaliumsulfit (45%)Potassium sulfite (45%) 109,840109.840 Kaliumcarbonatpotassium carbonate 283,340283.340 Diethylenglycoldiethylene glycol 73,34073.340 Dimezone SDimezone S 5,6605,660 1-Phenyl-5-mercapto-tetrazol1-phenyl-5-mercapto-tetrazole 0,0330.033 Ascorbinsäureascorbic acid 93,34093.340 Kaliumbromidpotassium 6,6606,660 Kalilauge 45%-ig, technischPotassium hydroxide 45%, technical 6,6606,660 (*) Diethylendiaminpentaessigsäure-Na(*) Diethylenediamine pentaacetic acid Na 55 -Salz-Salt

Beispiel 2: Entwickler für Röntgenfilm-Entwicklungsautomaten Example 2 Developer for X-ray Film Developers

Bestandteilcomponent Mengeamount [g/Liter Gebrauchslösung][g / liter working solution] Wasserwater ad 1000 mlad 1000 ml NaEDTANaEDTA 2,02.0 Kaliumhydrogensulfitpotassium hydrogen 15,315.3 Kaliumcarbonatpotassium carbonate 60,060.0 NatriumtetraboratSodium tetraborate 8,08.0 Triethylenglycoltriethylene 20,020.0 Ascorbinsäureascorbic acid 25,025.0 Natrium-IsoascorbatSodium isoascorbate 20,020.0 Natriumbromidsodium 4,54.5 5-Methylbenzotriazol5-methylbenzotriazole 0,30.3

Beispiel 3: Entwickler für Röntgenfilm-Entwicklungsautomaten Example 3 Developer for X-ray Film Developers

Bestandteilcomponent Mengeamount [g/Liter Gebrauchslösung][g / liter working solution] Wasserwater ad 1000 mlad 1000 ml Diethylentriaminpentaethansäurediethylenetriamine pentaacetic 1,761.76 Kaliumhydrogensulfitpotassium hydrogen 14,8314.83 Kaliumcarbonat (Pottasche)Potassium carbonate (potash) 75,0075.00 Kaliumhydroxidpotassium hydroxide 1,901.90 Diethylenglycoldiethylene glycol 22,022.0 Ascorbinsäure (BP2000/USP25)Ascorbic acid (BP2000 / USP25) 38,0038,00 4-Hydroxymethyl-4-methyl-1-phenyl-3-pyrazolidinon4-hydroxymethyl-4-methyl-1-phenyl-3-pyrazolidinone 1,701.70 Kaliumbromidpotassium 2,002.00 5-Mercapto-1-phenyl-1,2,3,4-tetrazol5-mercapto-1-phenyl-1,2,3,4-tetrazole 0,10.1

Beispiel 4: Entwicklerfamilie für Röntgenfilm-Entwicklungsautomaten Example 4 Developer Family for X-Ray Film Developers

Bestandteilcomponent Mengenbereichquantity range [g/Liter Gebrauchslösung][g / liter working solution] Wasserwater ad 1000 mlad 1000 ml Na5DTPANa 5 DTPA 1,00 bis 3,001.00 to 3.00 Kaliumsulfitpotassium 8,00 bis 19,008.00 to 19.00 Kaliumcarbonatpotassium carbonate 65,00 bis 95,0065.00 to 95.00 Diethylenglycoldiethylene glycol 20,00 bis 25,0020.00 to 25.00 Dimezone SDimezone S 1,00 bis 2,301.00 to 2.30 Ascorbinsäureascorbic acid 20,00 bis 35,0020.00 to 35.00 Kaliumbromidpotassium 1,00 bis 4,001.00 to 4.00 Kaliumhydroxidpotassium hydroxide 2,00 bis 4,002.00 to 4.00

Die nachstehende Tabelle gibt unterschiedlich bevorzugte Bereiche für Komponenten eines erfindungsgemäßen Entwicklers an. Unterschiedliche Komponenten, die die gleiche Funktion haben können auch in Kombination verwendet werden, wobei die Mengen so angepaßt werden, das der gewünschte Gesamteffekt erhalten wird. Funktions-beschreibung Komponenten Einsatzmenge in g/L Gebrauchslösung Einsatzmenge bevorzugt in g / L Gebrauchslösung Einsatzmenge besonders bevorzugt in g / L Gebrauchslösung Handelsname Lösungsmittel Wasser Komplexierungsmittel DTPA 0,8-3,0 0,8-2,5 0,8-2,5 EDTA-Salze 0,8-3,0 0,8-2,5 0,8-2,5 HEDTA 0,8-3,0 0,8-2,5 0,8-2,5 NTA 0,8-3,0 0,8-0,5 0,8-2,5 Oxidationsschutzmittel Kaliumhydrogensulfit 7,0-22,0 7,0-22,0 11,0-17,0 Kaliumdisulfit 4,0-12,0 8,0-12,0 8,0-12,0 Natriumbisulfit 7,0-22,0 7,0-22,0 11,0-17,0 Alkali / pH-Regulator Kaliumcarbonat 35,0-95,0 50,0-95,0 60,0-95,0 Borax 5,0-10,0 5,0-10,0 5,0-10,0 Natriummetaborat 5,0-13,0 5,0-13,0 8,0-13,0 Kaliumhydroxid 0,0-25,0 0,0-25,0 0,0-25,0 Natriumhydroxid 0,0-25,0 0,0-25,0 0,0-25,0 Lösungsvermittler Diethylenglycol 5,0-25,0 5,0-25,0 10,0-25,0 Triethylenglycol 5,0-25,0 5,0-25,0 10,0-25,0 Entwicklersubstanz Ascorbinsäure 15,0-45,0 15,0-45,0 22,0-40,0 Isoascorbinsäure 20,0-40,0 15,0-45,0 22,0-40,0 Dimezone S 1,0-4,0 1,0-4,0 1,0-3,0 Phenidon A 1,0-4,0 1,0-4,0 1,0-3,0 Phenidon B 1,0-4,0 1,0-4,0 1,0-3,0 Entwicklungsverzögerer Kaliumbromid 1,0-4,5 1,0-4,5 1,0-4,5 Natriumbromid 1,0-4,5 1,0-4,5 1,0-4,5 Antischleiermittel PMT 0,05 - 0,40 0,05 - 0,40 0,05 - 0,40 1 H-Benzotriazol 0,08 - 0,30 0,08 - 0,30 0,08 - 0,30 5-Methyl-1H-benzotriazol 0,08 - 0,30 0,08 - 0,30 0,08 - 0,30 6-Nitrobenzimidazol 0,20 - 0,45 0,20 - 0,45 0,20 - 0,45 5-Nitroindazol 0,20 - 0,45 0,20 - 0,45 0,20 - 0,45 The table below indicates differently preferred ranges for components of a developer according to the invention. Different components having the same function may also be used in combination, with the amounts adjusted to give the desired overall effect. Function description components Amount used in g / L working solution Amount used preferably in g / L working solution Use amount particularly preferred in g / L use solution trade name solvent water complexing DTPA 0.8-3.0 0.8-2.5 0.8-2.5 EDTA salts 0.8-3.0 0.8-2.5 0.8-2.5 HEDTA 0.8-3.0 0.8-2.5 0.8-2.5 NTA 0.8-3.0 from 0.8 to 0.5 0.8-2.5 Antioxidants potassium hydrogen 7.0 to 22.0 7.0 to 22.0 11.0 to 17.0 called potassium 4.0 to 12.0 8.0-12.0 8.0-12.0 sodium bisulfite 7.0 to 22.0 7.0 to 22.0 11.0 to 17.0 Alkali / pH regulator potassium carbonate 35.0 to 95.0 50.0 to 95.0 60.0 to 95.0 borax 5.0-10.0 5.0-10.0 5.0-10.0 sodium metaborate 5.0 to 13.0 5.0 to 13.0 8.0-13.0 potassium hydroxide 0.0 to 25.0 0.0 to 25.0 0.0 to 25.0 sodium hydroxide 0.0 to 25.0 0.0 to 25.0 0.0 to 25.0 solubilizers diethylene glycol 5.0 to 25.0 5.0 to 25.0 10.0-25.0 triethylene 5.0 to 25.0 5.0 to 25.0 10.0-25.0 developing substance ascorbic acid 15.0 to 45.0 15.0 to 45.0 22.0 to 40.0 isoascorbic 20.0 to 40.0 15.0 to 45.0 22.0 to 40.0 Dimezone S 1.0-4.0 1.0-4.0 1.0-3.0 Phenidone A 1.0-4.0 1.0-4.0 1.0-3.0 Phenidone B 1.0-4.0 1.0-4.0 1.0-3.0 development restrainer potassium 1.0-4.5 1.0-4.5 1.0-4.5 sodium 1.0-4.5 1.0-4.5 1.0-4.5 Antifoggants PMT 0.05-0.40 0.05-0.40 0.05-0.40 1 H-benzotriazole 0.08 - 0.30 0.08 - 0.30 0.08 - 0.30 5-methyl-1H-benzotriazole 0.08 - 0.30 0.08 - 0.30 0.08 - 0.30 6-nitrobenzimidazole 0.20 - 0.45 0.20 - 0.45 0.20 - 0.45 5-nitroindazole 0.20 - 0.45 0.20 - 0.45 0.20 - 0.45

Die oben beschriebenen Entwickler der Beispiele 1 bis 4 wurden in einem Entwicklungsautomaten für Röntgenfilme getestet, der unter der Bezeichnung 'Dürr-Automat 24PRO' vermarktet wird. Es handelt sich hierbei um eine Rollenmaschine, in welcher die Röntgenfilme durch zusammenarbeitende Rollenpaare nacheinander durch einen Tank mit Entwicklerflüssigkeit, einen Fixiertank und einen Wässerungstank bewegt werden. Der Automat ist im wesentlichen allseitig geschlossen, steht jedoch über einen Filmeinlass-Schlitz und einen Filmauslass-Schlitz mit der Umgebungsatmosphäre in Verbindung.The above-described developers of Examples 1 to 4 were tested in an X-ray film developing machine marketed under the name 'Dürr Automat 24PRO'. This is a roller machine in which the X-ray films are moved by cooperating pairs of rollers successively through a tank with developer liquid, a fixing tank and a watering tank. The machine is substantially closed on all sides but communicates with the ambient atmosphere via a film inlet slot and a film outlet slot.

Im Dauerbetrieb wurden mit den oben beschriebenen Entwicklern Standzeiten von bis zu sechs Wochen erzielt.In continuous operation, the developers described above achieved service lives of up to six weeks.

Die Konzentrationsangaben in der obigen Beschreibung und den Ansprüchen beziehen sich, wie angegeben, auf einen Liter Gebrauchslösung und nicht auf das Konzentrat. Die Konzentrationen im Konzentrat sind gemäß dem vorgeschriebenen Verdünnungsverhältnis für das Konzentrat größer. Dieses Verdünnungverhältnis liegt für einen praktischen Entwickler für Rollen-Entwicklungsmaschinen bei etwa 1,5 zu 5, für rollenfreie Entwicklungsmaschinen (Film wird an den Rändern geführt durch die Tanks bewegt) bei etwa 0,5 zu 1.The concentration data in the above description and claims refer, as indicated, to one liter of working solution and not to the concentrate. The concentrations in the concentrate are greater according to the prescribed dilution ratio for the concentrate. This dilution ratio is about 1.5 to 5 for a practical developer for roll-fed development machines, and about 0.5 to 1 for roll-free processors (film is moved around the edges by the tanks).

Claims (28)

Entwicklerkonzentrat für lichtempfindliches Filmmaterial mit einem Lösungsmittel auf Wasserbasis,
mit einem Einstellmittel, welches den pH-Wert des Lösungsmittels in alkalischen Bereich einstellt, und mit einem Entwicklungsmittel, dadurch gekennzeichnet, dass das Entwicklungsmittel Ascorbinsäure oder ein Salz der Ascorbinsäure umfasst und dass der pH-Wert so eingestellt ist, daß der pH-Wert der durch Verdünnen erhaltenen Gebrauchslösung zwischen etwa 8,5 und etwa 12 liegt.Developer concentrate for photosensitive film material with a water-based solvent,
with an adjusting agent which adjusts the pH of the solvent in the alkaline range, and with a developing agent, characterized in that the developing agent comprises ascorbic acid or a salt of ascorbic acid and that the pH is adjusted so that the pH of the by dilution use solution is between about 8.5 and about 12. Entwicklerkonzentrat nach Anspruch 1, dadurch gekenn zeichnet, dass der pH-Wert der Gebrauchslösung zwischen etwa 9,7 und etwa 11,2 liegt.A developer concentrate according to claim 1, characterized characterized marked in that the pH of the use solution is between about 9.7 and about 11.2 is located. Entwicklerkonzentrat nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass die Ascorbinsäure in einer Menge von etwa 15 g bis etwa 45 g, vorzugsweise etwa 22 g bis etwa 44 g, pro Liter Gebrauchslösung vorliegt.Developer concentrate according to claim 1 or 2, characterized in that the ascorbic acid is present in an amount of about 15 g to about 45 g, preferably about 22 g to about 44 g, per liter of working solution. Entwicklerkonzentrat nach einem der Ansprüche 1 bis 3,
dadurch gekennzeichnet, dass das Salz der Ascor binsäure in einer Menge von etwa 15 g bis etwa 40 g, vorzugsweise etwa 22 g bis etwa 40 g, pro Liter Gebrauchslösung vorliegt.Developer concentrate according to one of claims 1 to 3,
characterized in that the salt of Ascor binsäure is present in an amount of about 15 g to about 40 g, preferably about 22 g to about 40 g, per liter of working solution. Entwicklerkonzentrat nach einem der Ansprüche 1 bis 4,
dadurch gekennzeichnet, dass das Salz der Ascorbinsäure ein Alkali-Isoascorbat ist, insbesondere Natrium-Isoascorbat.Developer concentrate according to one of claims 1 to 4,
characterized in that the salt of ascorbic acid is an alkali isoascorbate, especially sodium isoascorbate. Entwicklerkonzentrat nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, dass es einen Entwicklungsverstärker enthält, vorzugsweise ein Pyrazol-Derivat.Developer concentrate according to one of claims 1 to 5, characterized in that it contains a development enhancer, preferably a pyrazole derivative. Entwicklerkonzentrat nach Anspruch 6, dadurch gekenn zeichnet, dass das Pyrazol-Derivat aus nachstehender Gruppe ausgewählt ist: 4-Hydroxymethyl-4-methyl-1-phenyl-3-pyrazolidinon, 1-Phenylpyrazolidin-3-on, 1-Phenyl-4-methyl-3-pyrazolidinon. A developer concentrate according to claim 6, characterized in that the pyrazole derivative is selected from the group below: 4-hydroxymethyl-4-methyl-1-phenyl-3-pyrazolidinone, 1-phenylpyrazolidin-3-one, 1-phenyl-4-methyl-3-pyrazolidinone. Entwicklerkonzentrat nach Anspruch 6 oder 7, dadurch gekennzeichnet, dass das Pyrazol-Derivat in einer Menge von etwa 0,05 g bis etwa 0,45 g, vorzugsweise etwa 0,20 bis etwa 0,40 g, pro Liter Gebrauchslösung vorliegt.Developer concentrate according to claim 6 or 7, characterized in that the pyrazole derivative is present in an amount of about 0.05 g to about 0.45 g, preferably about 0.20 to about 0.40 g, per liter of working solution. Entwicklerkonzentrat nach einem der Ansprüche 1 bis 8, gekennzeichnet durch ein Komplexierungsmittel, welches in einer Menge von etwa 0,8 g bis etwa 3 g , vorzugsweise etwa 0,8 g bis etwa 2,5 g, pro Liter Gebrauchslösung vorliegt.A developer concentrate according to any one of claims 1 to 8, characterized by a complexing agent which is present in an amount of from about 0.8 g to about 3 g, preferably from about 0.8 g to about 2.5 g, per liter of working solution. Entwicklerkonzentrat nach Anspruch 9, dadurch gekennzeichnet, dass das Komplexierungsmittel eine eine Stickstoffgruppe enthaltende schwach organische Säure oder ein Salz einer solchen ist.Developer concentrate according to claim 9, characterized in that the complexing agent is a nitrogen group-containing weak organic acid or a salt thereof. Entwicklerkonzentrat nach Anspruch 10, dadurch gekennzeichnet, dass das Komplexierungsmittel aus der nach stehenden Gruppe ausgewählt ist: Diethyltriaminpentaethansäure, Ethylendiamintetraethansäure, Hydroxyethylethylendiamintriessigsäure, Nitrilotriethansäure, Salze der vorgenannten Säuren. Developer concentrate according to claim 10, characterized in that the complexing agent is selected from the group below: Diethyltriamine pentaethanoic acid, ethylenediaminetetraethanoic acid, hydroxyethylethylenediaminetriacetic acid, nitrilotriethanoic acid, salts of the aforementioned acids. Entwicklerkonzentrat nach einem der Ansprüche 1 bis 11, dadurch gekennzeichnet, dass das pH-Einstellmittel ein Salz einer schwachen Säure, insbesondere einer schwachen anorganischen Säure umfasst.Developer concentrate according to one of claims 1 to 11, characterized in that the pH adjusting agent comprises a salt of a weak acid, in particular a weak inorganic acid. Entwicklerkonzentrat nach Anspruch 12, dadurch gekennzeichnet, dass das Einstellmittel aus nachstehender Gruppe ausgewählt ist: Kaliumcarbonat, Natriumtetraborat, Natriummetaborat. Developer concentrate according to claim 12, characterized in that the adjusting means is selected from the following group: Potassium carbonate, sodium tetraborate, sodium metaborate. Entwicklerkonzentrat nach Anspruch 13, dadurch gekennzeichnet, dass das Kaliumcarbonat in einer Menge von etwa 35 g bis etwa 95 g, vorzugsweise etwa 50 g bis etwa 95 g, nochmals vorzugsweise etwa 60 g bis etwa 95 g, pro Liter Gebrauchslösung, bzw. das Natriumtetraborat in einer Menge von etwa 5 g bis etwa 13 g, pro Liter Gebrauchslösung bzw. das Natriummetaborat in einer Menge von etwa 5 g bis etwa 13 g, vorzugsweise etwa 8 g bis etwa 13 g, pro Liter Gebrauchslösung vorliegt.Developer concentrate according to claim 13, characterized in that the potassium carbonate in an amount of about 35 g to about 95 g, preferably about 50 g to about 95 g, more preferably about 60 g to about 95 g, per liter of working solution, or the sodium tetraborate in an amount of about 5 g to about 13 g, per liter of use solution or the sodium metaborate in an amount of about 5 g to about 13 g, preferably about 8 g to about 13 g, per liter of working solution. Entwicklerkonzentrat nach einem der Ansprüche 1 bis 14, dadurch gekennzeichnet, dass das pH-Einstellmittel eine Lauge umfaßt, insbesondere Kaliumhydroxid oder Natriumhydroxid.Developer concentrate according to one of claims 1 to 14, characterized in that the pH-adjusting agent comprises an alkali, in particular potassium hydroxide or sodium hydroxide. Entwicklerkonzentrat nach Anspruch 15, dadurch gekennzeichnet, dass das pH-Einstellmittel in einer Menge von etwa 1 g bis etwa 25 g pro Liter Gebrauchslösung vorliegt.Developer concentrate according to claim 15, characterized in that the pH adjusting agent is present in an amount of about 1 g to about 25 g per liter of working solution. Entwicklerkonzentrat nach einem der Ansprüche 1 bis 16, gekennzeichnet durch ein Entwicklungsverzögerungs mittel auf Halogenid-Basis.Developer concentrate according to one of Claims 1 to 16, characterized by a halide-based development delaying agent. Entwicklerkonzentrat nach Anspruch 17, dadurch gekennzeichnet, dass das Entwicklungsverzögerungsmittel Kaliumbromid und/oder Natriumbromid umfasst.Developer concentrate according to claim 17, characterized in that the development-delaying agent comprises potassium bromide and / or sodium bromide. Entwicklerkonzentrat nach Anspruch 17 oder 16, dadurch gekennzeichnet, dass das Entwicklungsverzögerungsmittel in einer Menge von etwa 1 g bis etwa 4,5 g pro Liter Gebrauchslösung vorliegt.Developer concentrate according to claim 17 or 16, characterized in that the development-delaying agent is present in an amount of about 1 g to about 4.5 g per liter of working solution. Entwicklerkonzentrat nach einem der Ansprüche 1 bis 19, gekennzeichnet durch ein Oxidationsschutzmittel auf Sulfit-Basis.Developer concentrate according to one of Claims 1 to 19, characterized by a sulfite-based antioxidant. Entwicklerkonzentrat nach Anspruch 20, dadurch gekennzeichnet, dass das Oxidationsschutzmittel gebildet ist durch Kaliumsulfit in einer Menge von etwa 8 g bis etwa 19 g pro Liter Gebrauchslösung oder Kaliumhydrogensulfit in einer Menge von etwa 7 g bis etwa 22 g, vorzusweise etwa 11 g bis etwa 17 g, pro Liter Gebrauchslösung, oder Kaliummetabisulfit in einer Menge von etwa 4 g bis etwa 12 g, vorzugsweise etwa 8 g bis etwa 12 g, pro Liter Gebrauchslösung oder Natriumhydrogensulfit in einer Menge von etwa 7 g bis etwa 22 g, vorzugsweise etwa 11 g bis etwa 17 g, pro Liter Gebrauchslösung.Developer concentrate according to claim 20, characterized in that the antioxidant is formed by potassium sulfite in an amount of about 8 g to about 19 g per liter of use solution or potassium hydrogen sulfite in an amount of about 7 g to about 22 g, preferably about 11 g to about 17 g, per liter of working solution, or potassium metabisulfite in an amount of about 4 g to about 12 g, preferably about 8 g to about 12 g, per liter of use solution or sodium hydrogen sulfite in an amount of about 7 g to about 22 g, preferably about 11 g to about 17 g, per liter of working solution. Entwicklerkonzentrat nach einem der Ansprüche 1 bis 21, gekennzeichnet durch ein Antischleiermittel auf Azol-Basis.Developer concentrate according to one of Claims 1 to 21, characterized by an azole-based antifoggant. Entwicklerkonzentrat nach Anspruch 22, dadurch gekennzeichnet, dass das Antischleiermittel aus folgender Gruppe ausgewählt ist: 5-Mercapto-1-phenyl-1,2,3,4-tetrazol, 1-H-Benzotriazol, 5-methylbenzotriazol, 6-Nitrobenzimidazol, 5-Nitroindazol. Developer concentrate according to claim 22, characterized in that the antifoggant is selected from the group consisting of: 5-mercapto-1-phenyl-1,2,3,4-tetrazole, 1-H-benzotriazole, 5-methylbenzotriazole, 6-nitrobenzimidazole, 5-nitroindazole. Entwicklerkonzentrat nach einem der Ansprüche 1 bis 23, dadurch gekennzeichnet, dass das Antischleiermittel in einer Menge von etwa 0,05 g bis etwa 0,45 g, vorzugsweise etwa 0,08 g bis etwa 0,4 g, pro Liter Gebrauchslösung vorliegt.Developer concentrate according to one of claims 1 to 23, characterized in that the antifoggant is present in an amount of about 0.05 g to about 0.45 g, preferably about 0.08 g to about 0.4 g, per liter of working solution. Entwicklerkonzentrat nach einem der Ansprüche 1 bis 24, gekennzeichnet durch einen Lösungsvermittler auf Glycol-Basis.Developer concentrate according to one of Claims 1 to 24, characterized by a glycol-based solubilizer. Entwicklerkonzentrat nach Anspruch 25, dadurch gekennzeichnet, dass der Lösungsvermittler aus nachstehender Gruppe ausgewählt ist: Diethylglycol, Triethylenglycol. Developer concentrate according to claim 25, characterized in that the solubilizer is selected from the group below: Diethyl glycol, triethylene glycol. Entwicklerkonzentrat nach einem der Ansprüche 24 bis 26, dadurch gekennzeichnet, dass der Lösungsvermittler in einer Menge von etwa 5 g bis etwa 25 g, vorzugsweise etwa 10 g bis etwa 25 g, pro Liter Gebrauchslösung vorliegt.Developer concentrate according to one of claims 24 to 26, characterized in that the solubilizer is present in an amount of about 5 g to about 25 g, preferably about 10 g to about 25 g, per liter of working solution. Entwicklerkonzentrat nach einem der Ansprüche 1 bis 27, dadurch gekennzeichnet, dass das Lösungsmittel Wasser ist.Developer concentrate according to one of claims 1 to 27, characterized in that the solvent is water.
EP07010793A 2006-06-04 2007-05-31 Developer concentrate Not-in-force EP1862852B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006026422A DE102006026422A1 (en) 2006-06-04 2006-06-04 developer concentrate

Publications (2)

Publication Number Publication Date
EP1862852A1 true EP1862852A1 (en) 2007-12-05
EP1862852B1 EP1862852B1 (en) 2009-11-04

Family

ID=38261701

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07010793A Not-in-force EP1862852B1 (en) 2006-06-04 2007-05-31 Developer concentrate

Country Status (4)

Country Link
EP (1) EP1862852B1 (en)
AT (1) ATE447727T1 (en)
DE (2) DE102006026422A1 (en)
DK (1) DK1862852T3 (en)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011456A1 (en) 1991-12-02 1993-06-10 E.I. Du Pont De Nemours And Company Improved developer systems for hydrazine containing films
JPH08211572A (en) 1995-02-03 1996-08-20 Fuji Photo Film Co Ltd Image forming method
US5587276A (en) 1995-01-23 1996-12-24 Fuji Photo Film Co., Ltd. Image formation method
JPH09197630A (en) 1996-01-24 1997-07-31 Fuji Photo Film Co Ltd Developer for halogenated silver photographic material and developing method using this developer
JPH09197628A (en) 1996-01-24 1997-07-31 Fuji Photo Film Co Ltd Image forming method
JPH09265161A (en) 1996-01-24 1997-10-07 Fuji Photo Film Co Ltd Image forming method
JPH09265162A (en) 1996-01-24 1997-10-07 Fuji Photo Film Co Ltd Image forming method
JPH10171076A (en) 1996-02-07 1998-06-26 Fuji Photo Film Co Ltd Image forming method
US5858611A (en) * 1994-10-14 1999-01-12 Fuji Photo Film Co., Ltd. Development processing method of silver halide black-and-white photographic material
EP0908764A1 (en) * 1997-10-06 1999-04-14 Agfa-Gevaert N.V. Method of processing a black-and-white silver halide photographic material
EP0969317A2 (en) * 1998-07-01 2000-01-05 Eastman Kodak Company Method of processing a photographic high contrast silver halide material
DE19834357A1 (en) * 1998-07-30 2000-02-17 Agfa Gevaert Ag Photographic black-and-white processing with ascorbic acid or derivative in developer, useful for film and paper, uses oligophosphate in stop or stop-fix bath

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011456A1 (en) 1991-12-02 1993-06-10 E.I. Du Pont De Nemours And Company Improved developer systems for hydrazine containing films
US5858611A (en) * 1994-10-14 1999-01-12 Fuji Photo Film Co., Ltd. Development processing method of silver halide black-and-white photographic material
US5587276A (en) 1995-01-23 1996-12-24 Fuji Photo Film Co., Ltd. Image formation method
JPH08211572A (en) 1995-02-03 1996-08-20 Fuji Photo Film Co Ltd Image forming method
JPH09197630A (en) 1996-01-24 1997-07-31 Fuji Photo Film Co Ltd Developer for halogenated silver photographic material and developing method using this developer
JPH09197628A (en) 1996-01-24 1997-07-31 Fuji Photo Film Co Ltd Image forming method
JPH09265161A (en) 1996-01-24 1997-10-07 Fuji Photo Film Co Ltd Image forming method
JPH09265162A (en) 1996-01-24 1997-10-07 Fuji Photo Film Co Ltd Image forming method
JPH10171076A (en) 1996-02-07 1998-06-26 Fuji Photo Film Co Ltd Image forming method
EP0908764A1 (en) * 1997-10-06 1999-04-14 Agfa-Gevaert N.V. Method of processing a black-and-white silver halide photographic material
EP0969317A2 (en) * 1998-07-01 2000-01-05 Eastman Kodak Company Method of processing a photographic high contrast silver halide material
DE19834357A1 (en) * 1998-07-30 2000-02-17 Agfa Gevaert Ag Photographic black-and-white processing with ascorbic acid or derivative in developer, useful for film and paper, uses oligophosphate in stop or stop-fix bath

Also Published As

Publication number Publication date
DE102006026422A1 (en) 2007-12-06
DK1862852T3 (en) 2010-03-22
ATE447727T1 (en) 2009-11-15
EP1862852B1 (en) 2009-11-04
DE502007001882D1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
DE2736886A1 (en) METHOD OF TREATING LIGHT SENSITIVE COLOR PHOTOGRAPHIC SILVER HALOGENIDE RECORDING MATERIALS
DE2740322A1 (en) COLOR PHOTOGRAPHIC DEVELOPMENT PROCESS
DE3029361C2 (en)
DE2439153A1 (en) PHOTOGRAPHIC BLEACH FIXING BATH
DE2343242A1 (en) PROCESS FOR DEVELOPING EXPOSED PHOTOGRAPHICAL FILMS AND FOR REGENERATING THE DEVELOPER SOLUTION
DE2321400A1 (en) PROCESS FOR DEVELOPING COLOR PHOTOGRAPHICAL MATERIALS
DE2803678A1 (en) PROCEDURE FOR MAINTAINING EQUAL DEVELOPMENT ACTIVITY OF PHOTOGRAPHICAL DEVELOPERS
EP1862852B1 (en) Developer concentrate
DE2527398A1 (en) DEVELOPMENT PROCESS FOR LIGHT-SENSITIVE, PHOTOGRAPHIC SILVER HALOGENIDE MATERIALS
DE2936081A1 (en) LIGHT SENSITIVE, PHOTOGRAPHIC SILVER HALOGENIDE RECORDING MATERIAL
DE1772123C2 (en) Process for developing recording materials containing silver halide
DE2554528A1 (en) BLEACH FIXER
DE2264986A1 (en) DEVELOPER SOLUTION FOR COLOR INVERSION DEVELOPMENT OF PHOTOGRAPHICAL RECORDING MATERIALS CONTAINING AT LEAST ONE HALOGENSILVER EMULSION LAYER
DE2440610A1 (en) PHOTOGRAPHIC RAPID DEVELOPER SOLUTIONS CONTAINING METAL CHELATE COMPOUNDS
DE945606C (en) Photographic developer
DE3919551A1 (en) Biodegradable bleach bath for photographic silver halide material - contg. ferric salt, chloride, persulphate, nitrate and hydroxy cpd. and/or amine
DE2137549C3 (en) Process for the desilvering of photographic bleach-fix baths
DE69632885T2 (en) Photographic conditioning solution containing polyaminocarboxylic acid as the sole antimicrobial agent and methods of use
DE19738120A1 (en) Ascorbic acid developer for rapid development of photographic silver halide without excessive fogging
DE1622919A1 (en) Photographic light-sensitive material
DE2129123A1 (en) Developer solution for black and white and color development
DE2101436A1 (en) Process for making material with dye images
DE19742490C1 (en) Photographic black=and=white reversal developer free from hydroquinone
DE2449325C2 (en)
DE1597488A1 (en) Improved photographic emulsion for the production of direct positive images

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17P Request for examination filed

Effective date: 20080112

17Q First examination report despatched

Effective date: 20080226

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OROCHEMIE GMBH & CO. KG

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 502007001882

Country of ref document: DE

Date of ref document: 20091217

Kind code of ref document: P

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
LTIE Lt: invalidation of european patent or patent extension

Effective date: 20091104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100304

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100304

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100215

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20100805

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100205

BERE Be: lapsed

Owner name: OROCHEMIE G.M.B.H. & CO. KG

Effective date: 20100531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100531

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100531

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100531

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091104

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 447727

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120531

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 502007001882

Country of ref document: DE

Representative=s name: WITTE, WELLER & PARTNER, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 502007001882

Country of ref document: DE

Representative=s name: WITTE, WELLER & PARTNER PATENTANWAELTE MBB, DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20180518

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20190702

Year of fee payment: 13

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20190531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190531

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502007001882

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201201